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http://dx.doi.org/10Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonally derived
mature CD5high B cells; however, the cellular origin of CLL is still unknown. Patients with
CLL also harbor variable numbers of CD5low B cells, but the clonal relationship of these cells
to the bulk disease is unknown and can have important implications for monitoring, treating,
and understanding the biology of CLL. Here, we use B-cell receptors (BCRs) as molecular
barcodes to first show by single-cell BCR sequencing that the great majority of CD5low
B cells in the blood of CLL patients are clonally related to CD5high CLL B cells. We investigate
whether CD5 state switching was likely to occur continuously as a common event or as a rare
event in CLL by tracking somatic BCR mutations in bulk CLL B cells and using them to
reconstruct the phylogenetic relationships and evolutionary history of the CLL in four pa-
tients. Using statistical methods, we show that there is no parsimonious route from a single
or low number of CD5low switch events to the CD5high population, but rather, large-scale
and/or dynamic switching between these CD5 states is the most likely explanation. The over-
lapping BCR repertoires between CD5high and CD5low cells from CLL patient peripheral
blood reveal that CLL exists in a continuum of CD5 expression. The major proportion of
CD5low B cells in patients are leukemic, thus identifying CD5low B cells as an important
component of CLL, with implications for CLL pathogenesis, clinical monitoring, and the
development of anti-CD5-directed therapies. Copyright  2016 ISEH - International Society
for Experimental Hematology. Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).þChronic lymphocytic leukemia (CLL) is characterized
by the accumulation of clonally derived mature
CD5þCD19þCD23þCD20þ B cells in the blood, bone
marrow, and secondary lymphoid organs [1]. CD5 is a
glycoprotein normally found on T cells and a subset of
immunoglobulin M (IgM)-secreting B cells known as B-
1a cells [2], as well as regulatory B cells [3], but not on
the majority of peripheral blood (PB) B cells in healthy
adults. Although expanded B-cell populations in CLL pa-
tients typically have high CD5 expression, the cellularo: Paul Kellam, Wellcome Trust Sanger Institute,
me Campus, Hinxton, Cambridge CB10 1SA, UK;
c.uk
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exphem.2016.09.010.
 2016 ISEH - International Society for Experimental Hem
/creativecommons.org/licenses/by/4.0/).
.1016/j.exphem.2016.09.010origin of CLL is still unknown. CD5 CLL B cells show
similar gene expression patterns to the healthy CD5þ
B-1a B cells [4], but differ significantly from these cells
with regard to other surface markers, exhibiting features
of either activation or anergy after antigenic interactions
[5]. As a result, there is still ambiguity as to whether
CD5 is a marker of activation rather than of B-cell subtype
[6]. The fluidity between CD5þ and CD5– states in normal
B cells is demonstrated in vitro by the induction of CD5
cell-surface expression in B2-B cells by stimuli such as
anti-IgM antibodies and phorbol 12-myristate-13-acetate
[7,8] and by downregulation of CD5 in CD5þ B-1a B cells
by exposure to cytokines [9].
CLL patients regularly harbor CD5low B cells, but the
relationship of these cells to the leukemic cell bulk is un-
known. If CD5low B cells formed part of the CLL clone,
then this would have important implications for monitoring,atology. Published by Elsevier Inc. This is an open access article under the
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CD5 expression is commonly used as a marker for CLL,
the presence of CD5low tumor B-cell populations would
suggest that the ‘‘true’’ tumor load in patients is underesti-
mated. Moreover, the identification of a CD5low subpopula-
tion in CLL would have significant implications for the
development of therapeutic anti-CD5 monoclonal anti-
bodies for CLL [10–12]. Furthermore, the study of the
cellular origin and molecular pathogenesis of CLL would
benefit from a better understanding of the diversity of
clonal B cells and the role of any CD5low subpopulation
[4] given that studies normally focus on the CD5þ/high
B-cell populations [13]. Here, we first demonstrate the het-
erogeneity of CD5 expression within CLL clones from in-
dividual patients and identify dynamic relationships
between CLL cells with high and low CD5 expression.
We then show for the first time that there exists a large-
scale dynamic relationship between CD5high and CD5low
B-cell populations in CLL, a phenomenon with implica-
tions for disease biology and treatment.Methods
Patient samples
PBmononuclear cells (PBMCs) were isolated from 10 mL of whole
blood from four healthy volunteers and four CLL patients using Fi-
coll gradients (GE Healthcare) for bulk-sequencing experiments.
Single-cell and bulk-cell flow sorting were performed using CD20-
FITC, CD19-PE, CD5-APC, and IgG-V450 (BD Biosciences) and
Aqua (for live-dead cell detection, Invitrogen) into 96-well plates
from 1.5–1.9  106 frozen PBMCs per individual. Total RNAwas
isolated using TRIzol (Invitrogen) and purified using the RNeasy
Mini Kit (Qiagen) including on-column DNase digestion according
to the manufacturer’s instructions. Research was approved by the
relevant institutional review boards and ethics committees (07/
MRE05/44). Patient information is listed in Supplementary Tables
E1–E3 (online only, available at www.exphem.org).
B-cell receptor (BCR) amplification and sequencing
Reverse transcriptase polymerase chain reactions were performed
using FR1 primers as described previously [14]. MiSeq libraries
were prepared using Illumina protocols and sequenced using
300-bp paired-end MiSeq (Illumina). MiSeq reads were filtered
for base quality (median O32) using QUASR [15] and paired-
end reads merged if they contained identical overlapping regions
of O65 bp or otherwise discarded. Non-Ig sequences were
removed and only reads with significant similarity to reference
Ig heavy chain variable (IgHV) genes in the international ImMu-
noGeneTics information system (IMGT) database [16] by BLAST
[17] were retained (!1  1010 E-value). Primer sequences were
trimmed from reads and sequences were retained for analysis only
if both forward and reverse primer sequences were identified and
sequence lengths were greater than 240 bp for MiSeq. Single-cell
BCR sequencing was performed as described previously [14], with
the number of PCR cycles increased to 50 and the PCR product
undergoing Sanger sequencing. Only wells with a single BCR
Sanger sequencing signal present were used in downstream
analyses.Network assembly and analysis
The network generation algorithm and network properties were
calculated as in Bashford-Rogers et al. [14]. Briefly, each vertex
represents a unique sequence in which relative vertex size is pro-
portional to the number of identical sequence reads. Edges were
generated between vertices that differed by single-nucleotide,
non-indel differences and clusters were collections of related, con-
nected vertices. Phylogenetic analyses were performed by align-
ment using Mafft [18] and maximum parsimony tree fitting
using Paup* [19].
Testing single versus common CD5þ/CD–-switching event
hypotheses
The hypothesis that a population of B-CLL clones with distinct
BCR sequences switched CD5high/CD5low states rather than a sin-
gle switching event can be tested statistically by calculating the
probability that an overlap of BCR sequences between CD5high
and CD5low samples can happen by chance given a single shared
sequence. If the BCR sequence length is l, and nucleotide distance
from the central BCR is d, and any position can become mutated
to any one of three other bases, then the number of potential muta-
tional combinations is defined by:
Number of combinations of mutations5

l!
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The hypergeometric test was used to determine the probability of
observing, between CD5high and CD5low samples, equal or greater
BCR sequence overlap than what would be expected by chance.
To test whether the CD5high and CD5low CLL B-cell BCR pop-
ulations had a tendency to co-cluster, the nucleotide distances be-
tween any two sequences within or between the CD5high and
CD5low CLL B-cell BCR populations was determined. The ratio
between the mean nucleotide distances within versus between
the CD5high and CD5low CLL B-cell BCR populations was calcu-
lated. By calculating this ratio from representatively sized random
samples of the data (bootstrapping), the p value that the CD5high
and CD5low CLL B-cell BCR populations were distinctly clusters
rather than random mixing was determined. Here we used 1000
bootstraps of the data to calculate the p value.Results
Single-cell sequencing reveals that CLL B cells have
heterogeneous CD5 surface expression
We first sought to determine whether CD5low B cells can
form part of the CLL clone in patients and to describe their
relationship to CD5high cells from the same CLL. Flow cy-
tometry and cell sorting were performed on PB from four
CLL patients (white blood counts ranged from
69.1  109 to 102.4  109/L) and four healthy age-
matched individuals (summarized in Supplementary Table
E1, online only, available at www.exphem.org). In agree-
ment with previous studies [1], we found considerably
higher proportions of CD5high B cells in the PB of all
four CLL patients studied (O96% of CD20þ B cells)
compared with healthy, age-matched controls (4.6–7.4%,
Figure 1. Comparative analysis of CD5high and CD5low B-cell populations in CLL patients and healthy individuals. (A) Bulk-cell total PBMC BCR
sequencing networks for CLL patients 1-3 with corresponding maximum cluster sizes and IgHV-J gene usage. Samples yielded 112,722, 222,801, and
151,777 BCR sequences for CLL patients 1, 2, and 3, respectively (after filtering for Ig similarity, length, and primer sequences removal according to
Bashford-Rogers et al. [14]). Sequencing networks are presented such that each vertex represents a unique BCR sequence in which relative vertex size is
proportional to the number of identical sequence reads. Edges were generated between vertices that differed by single-nucleotide, non-indel differences
and clusters were collections of related, connected vertices. The largest cluster sizes (CLL clusters) and corresponding IgHV-J combinations are indicated
above and below the networks, respectively. (B) Single-cell analysis of CD5high or CD5low B-cell populations: single-cell BCR sequencing of CD5high and
CD5low B cells from CLL patients 1, 2, and 3 was used to determine the frequencies of CLL cells in each B-cell subset. The number and percentage of
CD5high or CD5low B cells expressing BCRs matching (i.e., maximum of 3 bp difference from the dominant CLL BCR sequence) the CLL clone for
each CLL patient are indicated.
33R.J.M. Bashford-Rogers et al./ Experimental Hematology 2017;46:31–37p ! 0.005; Supplementary Fig. E1 and Supplementary
Table E4, online only, available at www.exphem.org). We
also identified in all patients detectable populations of
B cells with no or low-level expression of surface CD5
(w1.5-3.2% of B cells).
To study these CD5low B cells, we first determined the
clonal BCR sequences present in total PB lymphocytes,
which were dominated by the CLL lymphocytes, and
used these to mine identical sequences for clonal CLL cells
in flow-sorted CD5high/CD5low B-cell populations at the
single-cell level. BCRs are generated during B-cell devel-
opment by site-specific DNA recombination of V, (D),
and J genes, with nontemplate additions and deletions be-
tween genes. Therefore, each B-cell clone expresses a
unique BCR sequence and we have used BCR sequencing
previously to identify B cells originating from the same
clone [14]. Next-generation sequencing of BCRs from
cDNA of total PB B-cell populations from three CLL pa-
tients (two untreated and one previously treated with chlor-
ambucil/rituximab; Supplementary Tables E1 and E2,
online only, available at www.exphem.org) yielded between
112,722 and 222,801 BCR sequences (after filtering for Ig
similarity, length, and primer sequences removal according
to Bashford-Rogers et al. [14]). Network analysis was
applied to these PBMC bulk-cell sequencing datasets to
identify CLL clusters representing groups of highly related
BCR sequences [14], with each CLL patient sampleexhibiting enlarged clusters of related sequences (identical
IgHV-D-J rearrangements and joining regions), represent-
ingO85% of all BCR sequences (Fig. 1A). These enlarged
clusters corresponded to the BCRs expressed by the
expanded CLL clone, similar to previous studies [14].
The IgHV-J combinations for these clusters were defined
as IGHV4-34-IGHJ6, IGHV4-61-IGHJ4, and IGHV3-48-
IGHJ4 for CLL patients 1, 2, and 3 respectively (Fig. 1Bi).
After determining the CLL BCR sequences in bulk PB
samples, we confirmed the presence of CLL cells in both
the CD5high and CD5low B-cell subsets using single-cell
BCR sequencing. CD5high and CD5low single B cells were
sorted into 96-well plates (gating strategies in
Supplementary Figs. E2 and E3, online only, available at
www.exphem.org), where single-cell BCR amplification
and sequencing was performed. Successful amplification
of 42–82 single CD5high or CD5low cells per fluorescence-
activated cell sort was achieved per patient. Expectedly,
97.26–100% of single CD5high B cells expressed the CLL
clonotypic BCR sequence in each patient. Interestingly,
76.56–98.15% of CD5low BCR sequences also matched to
the CLL clone sequence (i.e., the sequence was identical
to a BCR present in the bulk CLL clonal cluster; Fig. 1B;
Supplementary Table E5, online only, available at www.
exphem.org). Only one BCR sequence was detected in
each single cell/well in all cases. Because putative co-
occupancy of the same well by both a CD5low non-CLL
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CLL BCR would produce two unique BCR sequences,
the detection of clonotypic cells in the CD5low wells indi-
cates that these cells truly form part of the CLL clone.
This demonstrates that the majority of CD5low B cells
form part of the CLL clone, at least in the three patients
studied here.Population structures are shared between CD5low and
CD5high B-cell populations in CLL patients, but not in
healthy individuals
Having established that CLL cells with identical BCRs are
present in both the CD5high and CD5low B-cell subsets by
single-cell analysis, we investigated the relationships be-
tween these two subsets. CD5high and CD5low B cells (all
CD20þ) from CLL patient 4 and two healthy individuals
were cell sorted, yielding O10,000 B cells per sample,
and high-throughput BCR sequencing was performed
(generating between 11,375 and 397,469 reads;
Supplementary Fig. E4 and Supplementary Table E5, on-
line only, available at www.exphem.org), along with BCR
sequencing of the unsorted B-cell population. There was
no overlap of identical BCR sequences observed between
the CD5high and CD5low B-cell populations between the
two healthy individuals (Fig. 2A and 2B); however, signif-
icant overlap was observed between the CD5high and
CD5low B-cell populations in the CLL patient (Fig. 2C).
Indeed, BCR sequence network analysis showed that the
expanded cluster in the total (unsorted) PBMCs
(comprising 99.85% of total BCR sequences with the
[IGHV3-7*02-IGHD3-10*02-IGHJ4*02] rearrangement,
Fig. 2Ei) corresponded to the same clones in the expanded
clusters in both the CD5high and CD5low B-cell samples
(comprising 92.27% and 68.8% of total BCR sequences,
respectively, Fig. 2Eii). Expanded clones were not
observed in the healthy B-cell samples (Supplementary
Table E6, online only, available at www.exphem.org).
The subclonal CLL BCR frequencies were highly corre-
lated between the CD5high and CD5low subsets
(R2 5 0.98143, Fig. 2C), revealing similar population
structures between the two CLL B-cell populations. ThisFigure 2. Comparison of CD5high and CD5low B-cell populations. Shown are plot
populations for healthy patient 1 (A), healthy patient 2 (B), and CLL patient 4 (C
patient 4, in whom there is an overlap between CD5low and CD5high samples, the
BCRs, as indicated. (D) Theoretical model of CD5-state switching: unidirectiona
CD5high to CD5low (scenario B), and bidirectional dynamics switching/alternatin
(occurring only from a single or low number of CLL B cells) or a common/con
lation). (E) Determining the dynamics of CD5 state-switching in CLL patient 4: B
for separated CD5high B cells (Eii, left) and CD5low B cells (Eii, right). The domi
parsimony phylogenetic tree of the CLL cluster generated using the combined C
lations from (Eii). The branch lengths are proportional to the number of base d
resulting tree tips are colored red if the BCR was observed in CD5low B cells
both CD5low and CD5high B cells. Bootstrapping was performed to evaluate the
for all branches). The overlap between CD5low and CD5high CLL BCR population
event originating from the central BCR (p ! 1010).suggests that the B-cell population structure is shared be-
tween the CD5high and CD5low B-cell subsets in CLL, un-
like the CD5high and CD5low B-cell subsets in healthy
individuals that exhibit unique B-cell populations. We
observed that this difference in repertoire in CLL is due
to the leukemic clone, in which there are no significant dif-
ferences in repertoire structure in either CD5high or CD5low
subsets once CLL clonal BCRs were removed from the
repertoires (Supplementary Fig. E5, online only, available
at www.exphem.org).BCR phylogenetics reveals co-evolution of the CD5low
and CD5high CLL B-cell populations
The shared clonal structure between CD5high and CD5low
CLL B cells suggests that either CLL B cells start from a
CD5high state and downregulate surface CD5, start from a
CD5low state and upregulate surface CD5, or alternate be-
tween the two states (Fig. 2D). To understand whether
CD5 state switching was likely to occur continuously (a
common event, randomly distributed over a phylogeny of
CD5high and CD5low BCR sequences) or as a rare event (at
a single point in CLL evolution, distributed along single lin-
eages of CD5high or CD5low BCR sequences), we determined
phylogenetic pattern of the CD5high and CD5low BCR se-
quences and the probability that an overlap of unique BCR
sequences between the CD5low and CD5high samples can
happen by chance after a single CD5 state-switching event.
The accumulation of mutations during CLL clonal expansion
leading to intraclonal diversification within the BCR allowed
us to reconstruct the phylogenetic relationships. Maximum
parsimony trees were fitted using the CLL BCR sequences
(i.e., BCRs represented in the largest network cluster) from
each of the sorted CD5low and CD5high B-cell subsets
(Fig. 2Eiii). The central BCR in both CD5high and CD5low
phylogenetic trees were identical, and was the most
frequently observed BCR in both samples (comprising
85.6% and 85.7% of total CLL BCRs respectively). The
star-like structures of both trees suggest that the original
CLL clones in both the CD5high and CD5low B-cell subsets
emerged from a single common ancestor, represented by
the same central BCR [20]. When fitting a maximums of the frequencies of individual BCRs between CD5low and CD5high B-cell
) as determined by sequencing the BCR repertoires using MiSeq. For CLL
least-squares regression line equation and R2 value was determined for all
l switch from CD5high to CD5low (scenario A), unidirectional switch from
g between states (scenario C). These processes can be either a rare event
tinuous event (occurring from a large percentage of the CLL B-cell popu-
CR sequence networks for total PBMCs (Ei) and BCR sequence networks
nant cluster sizes are indicated above each plot. (Eiii) Combined maximum
LL BCR sequences from the separated CD5high and CD5low B-cell popu-
ifferences from the central BCR sequence (evolutionary distance) and the
only, blue if observed in CD5high B cells only, and green if observed in
reproducibility of the trees, showing strong tree support (O90% certainty
s was significantly greater than that expected by a rare CD5 state-switching
36 R.J.M. Bashford-Rogers et al./ Experimental Hematology 2017;46:31–37parsimony tree of the combined CD5low and CD5high CLL
BCR sequences (Fig. 2Eiii), substantial overlap between
the BCR sequences was observed in two B-cell subsets. In
fact, significantly greater overlap between the CD5high and
CD5low CLL BCRs was observed than would be expected
if the CD5 state switch occurred only from cells expressing
the central CD5high CLL BCR or vice versa (hypergeometric
test p! 1010; Supplementary Table E7, online only, avail-
able from www.exphem.org). If switching from CD5high to
CD5low or from CD5low to CD5high were one-directional
and fixed/stabilized afterward, then the merged phylogenies
would be dominated by lineages of enduring BCRs fixed for
CD5high or CD5low cells. Furthermore, the CD5low and
CD5high sequences do not subcluster significantly into
distinct groups on the phylogenetic tree (p 5 0.509;
Supplementary Fig. E6, online only, available from www.
exphem.org), suggesting that there is no parsimonious route
to a single or low number of switch events followed by fixed
BCR sequence lineages in CD5high and CD5low CLL. This
study supports a hypothesis that CD5 state switching is
likely to occur as a common event and continuous switching
may occur, although not at an equal frequency as CD5high/
CD5low ratios in CLL do not tend to 1. Decreased CD5
expression corresponds with the normal development of
B cells to plasma cells [21] and it is possible that the CD5low
CLL population represents further differentiated CLL
subclones.Conclusions
Our study shows that CD5high and CD5low tumor B cells
were present in all CLL patients studied and displayed
very similar population structures as determined by the
phylogeny of their BCR repertoires. The overlapping
BCR repertoires between CD5high and CD5low cells from
CLL blood cells show that the disease encompasses a con-
tinuum of CD5 expression levels. This indicates that the
CD5 state of CLL cells is subject to changes in CD5 expres-
sion and the observed dominance of CD5high cells repre-
sents an equilibrated flux rather than a fixed state. Indeed,
if the CD5low CLL B-cell population were hierarchically
above (i.e., closer to or containing stem cells) the CD5high
population, then the CD5low CLL B-cell population would
be a more effective treatment target than CD5high. Alterna-
tively, if the CD5low CLL B-cell population is hierarchical-
ly below the CD5high CLL B-cell population (i.e., closer to
differentiation and/or apoptosis), then understanding how
CD5 expression can become downregulated may represent
a therapeutic approach. Indeed, we show that decreased
CD5 expression is associated with differences in CD81
and CD45 cell surface expression (Supplementary
Fig. E7, online only, available at www.exphem.org), which
may reflect biological differences between these groups of
CLL cells. Together, these data suggest that CD5low
B cells are an important component of CLL that may beable to propagate and act as a residual disease
population, with implications for understanding CLL path-
ogenesis, minimal residual disease, and developing anti-
CD5-directed therapies.Acknowledgments
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Supplementary Table E1. Patient sample information
Patient White blood cell count (109 cells/L) CLL Binet Stage Treatment status
CLL 1 70.3 A Untreated
CLL 2 102.4 C Untreated
CLL 3 95.3 A Chlorambucil, rituximab completed 2 years prior to sampling
CLL 4 69.1 C Untreated
Healthy individuals 1–4 Healthy range NA NA
NA 5 not applicable.
Supplementary Table E2. Patient clinical information
Patient Genomic abnormality
IgHV mutation status
(% identity, bp differences) Progression of disease
CLL 1 13q14.3 deletion Mutated (96.6%, 7bp) Progressive, chlorambucil then relapse,
bendamustine/rituximab responder.
CLL 2 13q deletion Unmutated (99.1%, 2 bp) Progressive at time of sampling, chlorambucil then relapse,
then rituximab/chlorambucil nonresponder.
CLL 3 Bi-allelic 13q deletion Unmutated (99.5%, 1 bp) Partial remission at time of sampling after rituximab/chlorambucil,
went onto idelalisib/rituximab after sampling, but relapsed.
CLL 4 Not detected Mutated (94.2%, 11bp) Progressive at time of sampling, rituximab nonresponder.
Patients were selected for this study presented with a range of different prognostic factors and follow up information to ensure that the trends observed here
could be generalized to multiple CLL subtypes. CLL 1, 2, and 3 exhibited 13q deletions, which are associated with good prognosis [1], and CLL 4 showed no
known genomic abnormalities. A further prognostic factor is the IgHV mutation status, where unmutated IgHV (displayed in CLL 1 and 4) has a significantly
inferior prognosis to mutated IgHV (displayed in CLL 2 and 3).
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Supplementary Table E3. Patient clinical information
Marker type
Genomic/chromosomal
markers Relative prognosis Reference
Deletions Deletions in 11q, 17p Poor [1]
Deletions Deletions in 13q Good [1]
Deletions Deletion in 6q Intermediate [2]
Mutations TP53, ATM (tumor
suppressor genes)
Poor [3]
Mutations IRF4, Bcl-2 polymorphism Good [4]
Mutations Bcl-6 mutation Poor [5]
Mutations MDM2 SNP Poor [6]
IgVH mutational status IgVH mutated Good [7–10]
IgVH unmutated Poor
Gene expression ZAP-70 (correlates with
mutational status)
Poor [1]
V3-21 gene usage Poor [1]
MicroRNAs MicroRNA signature
associated with prognosis
- [11]
Telomere length Longer telomere length
(correlates with mutational
status)
Good [12]
Supplementary Table E4. Percentage of CD5high and CD5low B cells of total B cells in CLL and healthy patients’ peripheral blood
Single-cell experiment Bulk-cell experiment
Total B cells*CD5
low CD5high CD5low CD5high
CLL 1 1.551 98.449 - - 6381
CLL 2 3.208 96.792 - - 6826
CLL 3 2.968 97.032 - - 6975
Healthy individual 1 95.376 4.624 - - 757
Healthy individual 2 92.580 7.420 - - 283
CLL 4 - - 1.751 98.249 9993
Healthy individual 3 - - 92.837 7.163 2080
Healthy individual 4 - - 94.315 5.685 1970
*Total number of sorted CD19þCD20þCD5þ/ B cells.
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Supplementary Table E5. Percentage of reads from the maximum BCR clone in the CD5high and CD5low B-cell populations in CLL and healthy
individuals
Sequencing method
% CLL sequences* Total number of sequencesy
CD5low CD5high CD5low CD5high
CLL 1 Single-cell 76.56 ND 64 ND
CLL 2 Single-cell 96.34 100.00 82 80
CLL 3 Single-cell 98.15 97.62 54 42
CLL 4 Bulk-cell 68.80 99.85 109775 397469
Healthy individual 3 Bulk-cell NA NA 206201 149673
Healthy individual 4 Bulk-cell NA NA 194555 11375
ND 5 not determined; NA 5 not applicable.
*Sequences within 5bp of sequences in the largest cluster.
ySingle-cell sequencing performed by Sanger sequencing and bulk-cell sequencing performed by MiSeq.
Supplementary Table E6. Maximum cluster sizes as a percentage of
total BCR reads for CLL 4, healthy individual 3, and healthy individual 4
Maximum cluster size (% of total network)
CD5high B cells CD5low B cells
CLL 4 99.85 68.8
Healthy individual 3 4.62 2.19
Healthy individual 4 21.17 3.1
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Supplementary Table E7. Probabilities of BCR repertoire overlap between CD5high and CD5low populations in patient CLL 4 occurring by chance given a
single switch event
Distance from central BCR Number of CD5low BCRs
BCRs observed in both
CD5low and CD5high
populations Number of CD5high BCRs p value of observed overlap
1 613 581 584 !10  10–10
2 3749 522 714 !10  10–10
3 486 47 69 !10  10–10
4 28 1 3 1.05  10–8
5 1 1 2 !10  10–10
Supplementary Figure E1. Comparative analysis of CD5high and CD5low B-cell populations in CLL patients and healthy individuals. (A) Peripheral blood
mononuclear cell-surface expression of CD5 and CD20. CLL patients showed a higher proportion of CD20þ B cells with high CD5 cell-surface expression
compared to healthy individual samples. One representative sample is shown for each. (B) The percentages of CD5high and CD5low B cells (CD20þ) in four
CLL patients and four healthy individuals, with unpaired t-test p values indicated above sample groups. Error bars indicate mean þ SD.
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Supplementary Figure E2. Optimizing gates for single-cell FACS sorting using beads. Polystyrene microparticle beads were mixed with the fluorochrome-
conjugated human antibodies to optimize fluorescence gating settings for flow cytometric single-cell sorting of CD5high and CD5low B cells. After gating of
monomeric microparticle beads, indicated by the red gates in part (i) in each panel, the (A) CD5high and CD5low gates (red and green, respectively) were set
around the positive and negative control CD5 microparticle beads, (B) CD19 positive gates (blue), and (C) CD20 positive gates (blue).
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Supplementary Figure E3. Single-cell flow sorting of CD5high and CD5low B cells. The gating strategy used for identification of CD5high and CD5low
mature peripheral blood B cells in the single-cell experiments for (A) CLL patient 1, (B) CLL patient 2, (C) CLL patient 3, (D) healthy individual 1,
and (E) healthy individual 2. After exclusion of debris using light scatter features of leukocytes (panels (i)) and exclusion of dead cells (panels (ii)), mature
B cells were identified as CD19þCD20þ (panels (iii)). Events captured in the red gate in panels (iv) were identified as CD5high, and those captured in green
gate were identified as CD5low. Gates were chosen based on bead experiments (Supplementary Fig. E1).
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Supplementary Figure E4. Bulk-cell flow sorting of CD5high and CD5low B cells. The gating strategy used for identification of CD5high and CD5low mature
peripheral blood B cells in the bulk-cell experiments for (A) CLL patient 4, (B) healthy individual 3, and (C) healthy individual 4. After exclusion of debris
using light scatter features of leukocytes (panels (i)) and exclusion of dead cells (panels (ii)), mature B cells were identified as CD20þ (panels (iii)). Events
captured in the dark-blue gate in panels (iii) were identified as CD5high, and those captured in light-blue gate were identified as CD5low.
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A B
Supplementary Figure E5. Analysis A.of the nonleukemic counterpart of CD5þ/– B-cell populations in CLL patients. (A) Comparisons of the largest clus-
ter sizes (as a percentage of total reads) and (B) hierarchical clustering of IgHV-J gene usage similarities between CD5high (red) and CD5low (green) B-cell
populations for two healthy individuals and CLL patient 4 (either for all reads in the sample, or all reads that were unrelated to the CLL clone, defined asO30
bp differences and/orO10 gaps within an alignment from the CLL clonal sequence). The CD5high and CD5low samples from patient 4 have increased clon-
ality compared to healthy individuals (Supplementary Fig. E5A). However when the sequences related to the CLL clone are removed from the CD5high and
CD5low samples (i.e., the nonleukemic counterpart of the repertoire), there is no significant difference in clonality of V-J gene usage frequencies. Both
CD5high and CD5low samples from CLL patient 4, when excluding the CLL clone, cluster together with the healthy individuals.
Supplementary Figure E6. Testing the sub-clustering of CD5high and CD5low BCR sequences in the CLL BCR sequences in CLL patient 4. (A) Histogram
of the nucleotide distances between any two sequences within the CD5low (red) or CD5high (green) or between the sequences of the CD5high and CD5low
subsets (blue). The three subsets showed indistinguishable distributions of nucleotide distance distributions suggesting that the CD5high and CD5low CLL
B cells are co-clustered. (B) To determine whether the CD5low and CD5high sequences subcluster into distinct groups on the phylogenetic tree (where the
null hypothesis is that they are randomly distributed on the phylogenetic tree), the distances were randomly sampled at the same proportions, and the his-
togram of distance ratios of within groups versus between groups was calculated for each iteration. The p value for which the observed data distance ratio was
nonrandom is not significant (bootstrapped p 5 0.509), suggesting that the null hypothesis should be accepted and the sequences that generate the pairwise
distances are randomly distributed on the tree (i.e., there is no parsimonious route to a single or low number of switch events).
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Supplementary Figure E7. Testing the cell surface expression differences between CD5high and CD5low from 4 CLL patients. (A) The gating strategy used
for identification of CD5high and CD5low peripheral blood B cells from PBMC samples, where CD5high cells were defined as greater than 1.05 (median CD5
fluorescence in the CD19þCD45þ lymphocytes, green gate) and CD5low were defined as less than 0.95  (median CD5 fluorescence in the CD19þCD45þ
lymphocytes, blue gate). (B) The corresponding boxplots of the mean of fluorescence (MFI) between the CD5high and CD5low B-cell populations for (i)
CD81, (ii) CD22, (iii) CD38, (iv) CD20, (v) CD19, and (vi) CD45. p values were calculated as paired two-tailed t-tests. (C) Violin plots of the numbers
of mutations in the CD5high and CD5low BCR sequences from the sequencing data in Figure 2. **** p value! 106. Flow-cytometric fluorescence intensities
of fluorophore-conjugated antibodies against a set of CLL-associated B-cell surface antigen (namely CD81, CD22, CD38, CD20, CD19, and CD45) were
used to quantify cell-surface expression in the CLL clone. Notably, the mean of fluorescence (MFI) for the expression of both CD45 and CD81 by circulating
CLL B cells was significantly lower for CD5low B cells compared to CD5high B cells (paired t-test p values of 0.011 and 0.00023, respectively; Supplementary
Fig. E7). CD45 is normally found on all leukocytes, where previous studies show CD45 plays a positive regulatory role during B-cell receptor signaling [13].
CD81 is usually expressed at high levels in normal germinal center B cells, and associated with mutated CLL. This is in agreement with our data, as the
CD5high CLL B cells are associated with a higher number of mutations within the CLL clone as well as higher CD81 levels.
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